Below is an image of an Eli Lilly letter which informs doctors in the UK that Prozac is no longer authorized for use in (so-called) premenstrual dysphoric disorder (PMDD). For a larger view, please click on the image.
AHRP InfoMail Return to Home Page Return to InfoMail Media Coverage List MediaCoverage News Stories on Human ResearchProtection andCommentary by Vera Hassner Sharav March 25, 2002 Federal Agency Does Not Adequately Enforce Federal Standards of Ethics andSafety. FYI The Boston Globe takes a critical look at the federalOffice of Human…
Psychiatry Research 117 (2003) 127Â135. Premature mortality in schizophrenia: a 7.5-year study. Maria G. Morgan , Paul J. Scully , Hanafy A. Youssef , a,b a,b a Anthony Kinsellac, John M. Owensa, John L. Waddingtona,b,* http://psychrights.org/Research/Digest/NLPs/MM-PsychRes2003.pdf (100 KB pdf via psychrights.org) Abstract While premature death in schizophrenia is well recognised,…
Date: Wed, 15 May 2002 12:57:32 -0400 Subject: Harvard President Laments China Study_Globe ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) A Human Rights Organization www.researchprotection.org Contact: Vera Hassner Sharav FYI Harvard’s genetic experiments in rural China have elicited much criticism. In December 2000, The Washington Post published a highly critical investigative…
Documents Show Drug Company Promotion of Unproven Drug_NYT Tue, 29 Oct 2002 Internal company documents unsealed in a federal lawsuit reveal how the unholy alliance between doctors and drug companies has corrupted medical practice and defrauded the US taxpayer. Although it is illegal for drug companies to promote a drug…
Canadian Regulators Withdraw ADD Drug Linked to 20 Sudden Deaths Thu, 10 Feb 2005 Canadian regulators – but not the FDA – have withdrawn a Adderall, a pssychostimulant drug prescribed for children with so-called ADHD that has been linked to 20 sudden deaths linked to the drug – of which…
FDA Is Flexing Less Muscle where Safety is the Issue – Wash Post Thu, 18 Nov 2004 The Washington Post examines FDA’s record of surveillance and the evidence is clear: since 1992 when Congress required drug companies to pay users fees to the FDA, the agency’s focus changed from safety…
